| Informational notice: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting, changing, or stopping any medication. GLP-1 medications require a prescription from a licensed healthcare provider. Eligibility is determined on a case-by-case basis. |
In This Guide
- Understanding Why GLP-1 Treatments Are So Expensive
- A Breakdown of GLP-1 Pricing Without Insurance Coverage
- Navigating the Cost of GLP-1s with Insurance Plans
- Clarifying GLP-1 Pricing for Medicare and Medicaid Patients
- Analyzing Compounded GLP-1 Medication Costs and Risks
- How to Use Available Savings Programs from Manufacturers
- More Practical Ways to Save on GLP-1s in 2026
- Comparing Prices from Top Telehealth Weight Loss Services
- The Future Outlook for GLP-1 Affordability and Access
- Frequently Asked Questions About GLP-1 Treatment Pricing
Key Takeaways
Q: What drives GLP-1 treatment pricing so high for patients?
A: Billions in R&D costs, complex biologics manufacturing, limited manufacturer competition, and surging demand all keep GLP-1 treatment pricing above $1,000/month for most branded options.
Q: How much can compounded GLP-1 medication costs save compared to brand-name versions?
| Important: Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. They are prepared by licensed compounding pharmacies and prescribed on an individual basis by a licensed healthcare provider. |
A: Compounded GLP-1 medication costs typically range from $150 to $500 per month — significantly less than branded alternatives based on approximate list price comparisons. Actual savings vary by dosage, pharmacy, and plan. Patients must verify pharmacy accreditation and confirm current legal availability, as compounding is permitted only during documented FDA drug shortage periods.
Q: What is the outlook for GLP-1 pricing for Medicare enrollees?
A: GLP-1 pricing for Medicare patients is improving as Part D plans begin covering weight management indications, and future drug price negotiations under the Inflation Reduction Act could further reduce out-of-pocket costs.
Q: How do available savings programs from manufacturers lower GLP-1 treatment pricing?
A: Savings cards from Novo Nordisk and Eli Lilly can reduce copays to as little as $0 for commercially insured patients, though government-insured individuals are excluded and annual caps apply.
Q: Can telehealth providers like LevelsRx help reduce the cost of GLP-1s with insurance or without?
A: Telehealth services such as LevelsRx bundle consultations, monitoring, and medication fulfillment into transparent pricing, which may make the overall cost of GLP-1s more manageable than coordinating care through traditional channels. GLP-1 medications require a valid prescription following a medical evaluation.
Q: Are there practical ways to save on GLP-1s using tax-advantaged accounts?
A: Paying for GLP-1 prescriptions with HSA or FSA pre-tax dollars is one of the most overlooked ways to save on GLP-1s, potentially reducing effective costs depending on your individual marginal tax rate. Consult a tax advisor to confirm eligibility and savings.
Q: When will biosimilar competition meaningfully affect GLP-1 treatment pricing?
A: Biosimilar versions of semaglutide are in development, but significant GLP-1 treatment pricing reductions from generic-like competition are unlikely before the late 2020s as key patents expire.
Understanding Why GLP-1 Treatments Are So Expensive
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) represent a significant pharmaceutical development for treating type 2 diabetes and obesity. However, their price tags reflect years of research investment, complex manufacturing processes, and limited market competition. Understanding the forces behind GLP-1 treatment pricing helps patients make informed decisions about how to manage their expenses.
Research and Development Costs
Novo Nordisk and Eli Lilly each invested billions of dollars over more than a decade to bring their GLP-1 medications to market. Clinical trials for weight management indications alone involved tens of thousands of participants across multiple phases. These costs are factored into the retail price of every prescription.
Biologics Manufacturing Complexity
Unlike simple chemical compounds, GLP-1 medications are peptide-based biologics that require specialized manufacturing facilities. The injectable delivery systems, temperature-controlled supply chains, and stringent quality control processes all contribute to higher production costs compared to traditional oral medications.
Limited Competition and Patent Protections
Only two major manufacturers currently dominate the branded GLP-1 market. Patent protections prevent generic versions from entering the market for years, which keeps pricing power firmly in the hands of Novo Nordisk and Eli Lilly. Until patents expire or additional competitors gain FDA approval, patients face limited negotiating leverage.
Surging Demand and Supply Constraints
Demand for GLP-1 medications has outpaced manufacturing capacity since their widespread adoption for weight loss. Periodic shortages have reduced the competitive pressure that might otherwise drive prices down. When supply is constrained, manufacturers and pharmacies have little incentive to discount.
- Branded semaglutide (Wegovy): List price exceeds $1,300 per monthBranded semaglutide (Wegovy):
- Branded tirzepatide (Zepbound): List price ranges from $1,000 to $1,060 per monthBranded tirzepatide (Zepbound):
- Branded liraglutide (Saxenda): List price approximately $1,400 per monthBranded liraglutide (Saxenda):
A Breakdown of GLP-1 Pricing Without Insurance Coverage
For patients paying entirely out of pocket, GLP-1 pricing without insurance coverage can be staggering. Monthly costs for branded medications routinely exceed $1,000, and annual expenses can surpass $15,000. Knowing the approximate figures helps you budget realistically and identify where savings may be possible.
Retail Prices at Major Pharmacies
Retail pricing varies by pharmacy, dosage, and geographic location. The following table provides approximate monthly costs for the most commonly prescribed GLP-1 medications at standard retail pharmacies without any insurance or discount applied. Prices are subject to change.
| Medication | Indication | Approximate Monthly Retail Price |
| Ozempic (semaglutide) | Type 2 Diabetes | $900 – $1,100 |
| Wegovy (semaglutide) | Weight Management | $1,300 – $1,400 |
| Mounjaro (tirzepatide) | Type 2 Diabetes | $1,000 – $1,100 |
| Zepbound (tirzepatide) | Weight Management | $1,000 – $1,060 |
| Saxenda (liraglutide) | Weight Management | $1,300 – $1,500 |
Why Cash Prices Vary Between Pharmacies
Pharmacy benefit structures, wholesaler agreements, and regional pricing all create significant variation. A patient filling the same prescription at CVS, Walgreens, or a local independent pharmacy may see price differences of $100 or more. Online pharmacy platforms and services like LevelsRx can sometimes offer more competitive pricing by streamlining the dispensing process and reducing overhead costs.
The True Annual Cost Without Coverage
At an average of $1,200 per month, a patient paying full retail for a branded GLP-1 medication will spend approximately $14,400 per year. For many households, this is a significant financial commitment. This reality is why exploring every available discount, alternative formulation, and coverage pathway is important.
Dosage Escalation and Its Impact on Price
Most GLP-1 treatment protocols begin at a lower dose and gradually increase over several months. While starting doses may cost slightly less, maintenance doses at the higher end of the range often carry the full list price. Patients should factor in the entire titration schedule when estimating their total out-of-pocket commitment.
Navigating the Cost of GLP-1s with Insurance Plans
The cost of GLP-1s with insurance depends heavily on the type of plan, the specific formulary, and whether the medication is prescribed for diabetes or weight management. Insurance can dramatically reduce monthly expenses, but coverage is far from guaranteed, and many patients encounter frustrating barriers.
Employer-Sponsored Plans
Many large employer-sponsored health plans cover GLP-1 medications for type 2 diabetes management. Coverage for weight loss indications is less consistent. Some employers have added anti-obesity medication benefits in response to employee demand, while others have explicitly excluded them due to cost concerns.
- Tier placement matters: GLP-1s placed on specialty tiers typically carry copays of $100 to $300 per month
- Prior authorization: Most insurers require documented medical necessity, BMI thresholds, or evidence of failed lifestyle interventions
- Step therapy: Some plans require patients to try older, less expensive medications first
- Quantity limits: Insurers may restrict the number of pens or doses covered per fill
ACA Marketplace Plans
Affordable Care Act marketplace plans vary widely by state and carrier. Some silver and gold tier plans include GLP-1 coverage for diabetes, but weight management coverage remains uncommon on the exchanges. Patients should review the formulary of any marketplace plan before enrolling during open enrollment.
How to Appeal a Coverage Denial
If your insurer denies coverage for a GLP-1 medication, you have the right to appeal. Work with your prescribing physician to submit a letter of medical necessity that includes your diagnosis, BMI, comorbidities, and documentation of previous treatment attempts. Many denials are overturned on first or second appeal when supported by thorough clinical evidence.
Checking Your Formulary Before Filling
Before assuming your plan covers a specific GLP-1, call the number on the back of your insurance card or use your insurer’s online formulary tool. Ask specifically about your medication, dose, and whether it is covered under the pharmacy benefit or the medical benefit. This single step can prevent costly surprises at the pharmacy counter.
Clarifying GLP-1 Pricing for Medicare and Medicaid Patients
GLP-1 pricing for Medicare enrollees has been a topic of significant policy discussion. Medicare Part D has historically excluded coverage for weight loss medications, creating a major gap for older adults who could benefit from these treatments. Recent legislative changes have started to shift this landscape.
Medicare Part D and Anti-Obesity Medications
The Treat and Reduce Obesity Act and subsequent legislative efforts have pushed for Medicare coverage of FDA-approved anti-obesity medications. As of 2026, Medicare Part D plans are beginning to cover certain GLP-1 medications for weight management in addition to their existing coverage for type 2 diabetes indications. However, coverage specifics vary by plan, and beneficiaries should verify their individual Part D formulary.
Medicare Advantage Plan Variations
Medicare Advantage plans offered by private insurers may provide broader GLP-1 coverage than traditional Medicare. Some Medicare Advantage plans have included supplemental benefits that cover anti-obesity medications, though copays and prior authorization requirements differ significantly between carriers.
- UnitedHealthcare Medicare Advantage: Select plans cover semaglutide for diabetes; weight loss coverage varies by region
- Humana Medicare Advantage: Formulary placement and copay tiers differ by plan year
- Aetna Medicare Advantage: Some plans require step therapy before approving GLP-1s
Medicaid Coverage by State
Medicaid coverage for GLP-1 medications is determined at the state level and varies considerably. Most state Medicaid programs cover GLP-1s for type 2 diabetes, but coverage for obesity as a standalone indication remains limited. Patients should contact their state Medicaid office or managed care organization to confirm eligibility and any prior authorization requirements.
The Impact of the Inflation Reduction Act
The Inflation Reduction Act’s provisions for Medicare drug price negotiation could eventually affect GLP-1 pricing for Medicare patients. As the list of negotiated drugs expands in coming years, high-cost medications like semaglutide and tirzepatide may become candidates for direct price negotiation between CMS and manufacturers, potentially lowering out-of-pocket costs for millions of beneficiaries.
Analyzing Compounded GLP-1 Medication Costs and Risks
| Required disclosure: Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. They are prepared by licensed compounding pharmacies under state and federal oversight and dispensed pursuant to individual prescriptions from licensed healthcare providers. Compounding of GLP-1 medications is legally permitted only during documented FDA drug shortage periods. |
Compounded GLP-1 medication costs are typically a fraction of branded prices, making compounding pharmacies an option for cost-conscious patients during periods when compounding is legally permitted. However, this lower price comes with important considerations regarding safety, legality, and clinical evaluation that every patient should understand before choosing this route.
What Are Compounded GLP-1 Medications?
Compounded semaglutide and tirzepatide are versions of these medications prepared by compounding pharmacies rather than the original manufacturers. They are not the same products as their brand-name counterparts and are not FDA-approved finished drug products. During periods of FDA-recognized drug shortages, 503A (individual prescription) and 503B (outsourcing facility) compounding pharmacies have been permitted to produce these medications. Compounded versions typically cost between $150 and $500 per month, which may represent meaningful savings compared to branded alternatives based on list price comparisons. Actual savings vary.
Safety and Quality Considerations
Not all compounding pharmacies maintain the same quality standards. Patients considering compounded GLP-1s should look for pharmacies that meet the following criteria:
- Registered with the FDA as a 503B outsourcing facility or licensed as a 503A pharmacy in their state
- Accredited by the Pharmacy Compounding Accreditation Board (PCAB)
- Provide certificates of analysis and third-party purity testing for each batch
- Use pharmaceutical-grade ingredients sourced from FDA-registered suppliers
- Maintain proper cold-chain shipping and storage protocols
| Safety notice: GLP-1 receptor agonists including semaglutide and tirzepatide carry an FDA black box warning for thyroid C-cell tumors observed in animal studies. It is currently unknown whether this risk applies to humans. Do not use these medications if you or a family member has a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. More serious risks include pancreatitis and gallbladder disease. Discuss all risks with your healthcare provider before starting treatment. |
The FDA Shortage List and Legal Status
The legality of compounded semaglutide and tirzepatide is directly tied to the FDA’s drug shortage list. When a medication is listed as being in shortage, compounding pharmacies can legally produce copies. If the shortage is resolved and the drug is removed from the list, compounding pharmacies must cease production of that specific compound. Patients should stay informed about the current shortage status of their medication, as this directly affects availability.
Providers Offering Compounded Options
Several telehealth platforms and weight management clinics offer compounded GLP-1 medications as part of their treatment programs. LevelsRx is among the providers that connect patients with licensed compounding pharmacies, offering transparent pricing and physician oversight throughout the treatment process. When evaluating any provider offering compounded medications, verify that they require a legitimate medical consultation and prescription before dispensing.
| Note: Compounded semaglutide and tirzepatide offered through telehealth platforms, including LevelsRx, are not FDA-approved products. They are distinct from the brand-name drugs Ozempic, Wegovy, Mounjaro, and Zepbound. GLP-1 medications require a prescription from a licensed healthcare provider. |
How to Use Available Savings Programs from Manufacturers
Both Novo Nordisk and Eli Lilly operate available savings programs designed to reduce the out-of-pocket burden for eligible patients. These programs can cut monthly costs significantly, but they come with specific eligibility requirements and limitations that patients need to understand.
Novo Nordisk Savings Programs
Novo Nordisk offers several assistance pathways for patients prescribed Ozempic, Wegovy, or Saxenda:
- Wegovy Savings Card: Eligible commercially insured patients may pay as little as $0 for a 28-day supply, with a maximum savings limit per fill and per calendar year
- Ozempic Savings Card: Commercially insured patients can reduce copays, with savings up to a specified annual maximum
- Novo Nordisk Patient Assistance Program (PAP): Uninsured patients who meet income requirements (typically below 400% of the federal poverty level) may receive medication at no cost
Eli Lilly Savings Programs
Eli Lilly provides similar support for patients prescribed Mounjaro or Zepbound:
- Zepbound Savings Card: Eligible commercially insured patients may pay a reduced copay per monthly fill
- LillyDirect: Eli Lilly’s direct-to-patient platform offers home delivery and, for some patients, lower pricing on Zepbound
- Lilly Cares Foundation: Income-eligible uninsured patients may qualify for free medication through this patient assistance program
Eligibility Restrictions to Know
Manufacturer savings programs almost universally exclude patients enrolled in government-funded insurance programs, including Medicare, Medicaid, Tricare, and VA benefits. This restriction is due to federal anti-kickback statutes. Additionally, most savings cards have annual caps on the total dollar amount of assistance provided, and they may expire or change terms at the beginning of each calendar year.
How to Enroll
Enrollment in manufacturer savings programs typically requires the following steps:
- Visit the manufacturer’s official website for the specific medication
- Complete an eligibility questionnaire confirming your insurance status and residency
- Download or request a savings card (physical or digital)
- Present the savings card to your pharmacist at the time of fill along with your insurance card
- Reactivate or re-enroll annually, as most programs reset each January
More Practical Ways to Save on GLP-1s in 2026
Beyond manufacturer programs and insurance optimization, there are several additional strategies that patients frequently overlook. These approaches can be combined for maximum impact on your monthly medication budget.
Use Prescription Discount Platforms
Platforms like GoodRx, RxSaver, and SingleCare aggregate discount pricing from participating pharmacies and can sometimes offer lower prices than insurance copays for certain medications. While the savings on branded GLP-1s through these platforms are typically modest, they can be more meaningful for compounded versions or if you are comparing cash prices across multiple pharmacies.
Consider Telehealth Weight Loss Services
Telehealth providers specializing in weight management often negotiate volume pricing with pharmacies and can pass savings along to patients. LevelsRx, for example, bundles physician consultations, ongoing monitoring, and medication fulfillment into a single transparent pricing structure, which may be more affordable than coordinating these services separately through traditional healthcare channels. A valid prescription following a medical evaluation is required.
Ask About Dose Optimization
Some patients achieve their clinical goals at lower maintenance doses than the maximum approved amount. Discuss with your physician whether a lower dose provides adequate benefit for your situation. A lower dose not only reduces medication costs but may also reduce side effects. Never adjust your dose without medical guidance.
Explore Flexible Spending and Health Savings Accounts
If your employer offers a Flexible Spending Account (FSA) or you have a Health Savings Account (HSA), GLP-1 medications prescribed for a qualifying medical condition are typically eligible expenses. Using pre-tax dollars may reduce your effective cost depending on your individual marginal tax rate. Consult a tax advisor to confirm eligibility and potential savings.
Stay Informed About Generic and Biosimilar Timelines
Several pharmaceutical companies are developing biosimilar versions of semaglutide and other GLP-1 medications. While branded patent protections extend into the late 2020s and beyond for some formulations, the eventual entry of biosimilars may reduce prices over time. Monitoring FDA approval timelines for these products can help you plan your long-term treatment budget.
Comparing Prices from Top Telehealth Weight Loss Services
The telehealth weight loss market has expanded rapidly, with numerous providers offering GLP-1 prescriptions paired with clinical support. Pricing structures vary considerably, and understanding what is included in each provider’s fee helps you make an accurate cost comparison.
| Prescription notice: GLP-1 medications require a valid prescription from a licensed healthcare provider. All telehealth providers listed below require a medical evaluation before prescribing. Eligibility is determined on a case-by-case basis. |
What to Compare Beyond the Sticker Price
When evaluating telehealth GLP-1 providers, the monthly medication price is only one component of total cost. Consider these additional factors:
- Consultation fees: Some providers charge separately for initial and follow-up physician visits
- Lab work requirements: Certain services require bloodwork that may or may not be included in the program fee
- Shipping costs: Medication delivery fees can add $10 to $30 per month
- Subscription commitments: Some platforms require multi-month commitments or charge cancellation fees
- Included support: Dietitian access, coaching, and progress tracking tools vary widely
Provider Pricing Overview
The following table offers a general comparison of pricing structures from several well-known telehealth weight loss services offering GLP-1 medications. Prices are approximate and subject to change. All compounded options are not FDA-approved.
| Provider | Medication Type | Approximate Monthly Cost (Medication + Service) | Includes Consultations |
| LevelsRx | Compounded / Branded | Varies by plan; transparent pricing | Yes |
| Hims/Hers | Compounded | $199 – $499 | Yes |
| Ro | Compounded / Branded | $149 – $499+ | Yes |
| Calibrate | Branded (insurance-based) | Program fee + insurance copay | Yes |
| Found | Branded / Compounded | $99 membership + medication cost | Yes |
Why Transparent Pricing Matters
Hidden fees and unclear billing practices are common complaints among patients using telehealth weight loss services. Providers like LevelsRx that publish clear, upfront pricing and explain exactly what is included in each plan help patients avoid unexpected charges. Before committing to any service, request a complete breakdown of all costs you will incur over the first three months of treatment.
Questions to Ask Before Enrolling
- Is the medication price locked in, or can it increase during my treatment?
- What happens if my medication is out of stock or discontinued?
- Are follow-up consultations included, and how frequently do they occur?
- Can I cancel at any time without penalty?
- Do you accept insurance, and will you help with prior authorization?
The Future Outlook for GLP-1 Affordability and Access
Several converging factors suggest that GLP-1 treatment pricing may shift meaningfully over the next few years. Legislative pressure, new market entrants, and evolving insurance policies are all contributing to a trajectory toward greater affordability, though the pace of change remains uncertain.
Oral GLP-1 Formulations
Novo Nordisk’s oral semaglutide (Rybelsus) is already available for type 2 diabetes, and higher-dose oral formulations for weight management are in late-stage clinical trials. Oral delivery eliminates the cost of injectable devices and cold-chain logistics, which could result in lower retail prices. If approved for weight loss at effective doses, oral semaglutide could become a more accessible entry point for patients.
Biosimilar and Generic Competition
As key patents begin to expire, biosimilar manufacturers are positioning to enter the GLP-1 market. Companies in multiple countries are already developing biosimilar semaglutide products. In other biologic categories, biosimilar competition has historically reduced prices in some cases, though outcomes vary and timelines are uncertain.
Expanding Insurance Coverage
Growing clinical evidence supporting the cardiovascular, renal, and metabolic benefits of GLP-1 medications is strengthening the case for broader insurance coverage. The FDA’s approval of semaglutide for cardiovascular risk reduction in addition to weight management has prompted several major insurers to reconsider their coverage exclusions. This trend is likely to continue as outcomes data accumulates.
Policy and Legislative Developments
Congressional efforts to mandate Medicare coverage of anti-obesity medications, combined with state-level initiatives to require commercial insurers to cover FDA-approved weight loss treatments, could fundamentally alter the affordability equation. Patients and advocacy organizations continue to push for these changes, and several bills addressing GLP-1 access are under active consideration.
What Patients Can Do Now
While waiting for systemic changes, patients can take proactive steps to manage their GLP-1 costs. Regularly reviewing your insurance plan during open enrollment, checking for updated manufacturer savings programs, and consulting with providers like LevelsRx about the most cost-effective treatment options available to you are all practical actions that can make a meaningful difference in your monthly spending.
Frequently Asked Questions About GLP-1 Treatment Pricing
| This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication. |
What is the average monthly cost of a GLP-1 medication without insurance?
Without insurance, branded GLP-1 medications like Wegovy, Ozempic, Mounjaro, and Zepbound typically cost between $900 and $1,400 per month at retail pharmacies. Compounded versions, when legally available during documented FDA shortage periods, may cost between $150 and $500 per month depending on the pharmacy and dosage. Compounded formulations are not FDA-approved.
Does insurance usually cover GLP-1 medications for weight loss?
Coverage varies significantly by plan. Most commercial insurers cover GLP-1 medications for type 2 diabetes, but coverage for weight management indications is less consistent. Employer-sponsored plans are increasingly adding anti-obesity medication benefits, but many still exclude them. Always verify your specific plan’s formulary before starting treatment.
Can Medicare patients get help paying for GLP-1 medications?
Medicare Part D covers GLP-1 medications prescribed for type 2 diabetes. Coverage for weight management indications under Medicare is expanding following recent legislative changes, but availability depends on your specific Part D or Medicare Advantage plan. Manufacturer patient assistance programs are generally not available to Medicare beneficiaries due to federal regulations.
Are compounded GLP-1 medications safe?
| Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. They do not undergo the same regulatory review as branded medications. |
Compounded GLP-1 medications prepared by licensed, accredited pharmacies using pharmaceutical-grade ingredients can be a legally available option for some patients during FDA shortage periods. Patients should only obtain compounded GLP-1s through a legitimate prescription from a licensed healthcare provider and a reputable compounding pharmacy. Discuss the risks and benefits with your provider before proceeding.
How can I find the lowest price for my GLP-1 prescription?
Start by comparing prices at multiple pharmacies using tools like GoodRx or RxSaver. Check whether you qualify for manufacturer savings cards or patient assistance programs. Explore telehealth providers like LevelsRx that may offer bundled pricing. If you have an HSA or FSA, consult a tax advisor about using pre-tax funds to reduce your effective cost. Finally, discuss dose optimization with your physician to ensure you are on the most appropriate regimen for your clinical needs.
Will GLP-1 medications become cheaper in the future?
Multiple factors point toward potential changes in GLP-1 pricing over time, including possible biosimilar competition, oral formulations, expanded insurance mandates, and potential Medicare drug price negotiations. However, significant price reductions from biosimilar entry are unlikely before the late 2020s at the earliest. In the meantime, leveraging available savings programs and exploring all coverage options remains the most effective strategy for managing costs.
Disclosures and Legal Notices
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or weight-loss program.
Compounded medications referenced in this article are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. They are prepared by licensed compounding pharmacies and dispensed pursuant to individual prescriptions issued by licensed healthcare providers. Compounding of GLP-1 medications is permitted only during documented FDA drug shortage periods.
GLP-1 medications require a prescription from a licensed healthcare provider. Eligibility is determined on a case-by-case basis following a medical evaluation.
Semaglutide and tirzepatide carry an FDA black box warning for thyroid C-cell tumors observed in animal studies. The relevance of this finding to humans is unknown. These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pricing figures in this article are approximate, based on publicly available information, and subject to change. Always verify current pricing directly with your pharmacy or provider.
